Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment

Author:

Okada Manabu12,Watarai Yoshihiko1,Iwasaki Kenta3,Murotani Kenta4,Futamura Kenta1,Yamamoto Takayuki1,Hiramitsu Takahisa1,Tsujita Makoto1,Goto Norihiko1,Narumi Shunji1,Takeda Asami5,Morozumi Kunio6,Uchida Kazuharu23,Kobayashi Takaaki2ORCID

Affiliation:

1. Department of Transplant and Endocrine Surgery; Nagoya Daini Red Cross Hospital; Nagoya Japan

2. Department of Renal Transplant Surgery; Aichi Medical University School of Medicine; Nagakute Japan

3. Department of Kidney Disease and Transplant Immunology; Aichi Medical University School of Medicine; Nagakute Japan

4. Division of Biostatistics; Clinical Research Center; Aichi Medical University Hospital; Nagakute Japan

5. Department of Nephrology; Nagoya Daini Red Cross Hospital; Nagoya Japan

6. Department of Nephrology; Masuko Memorial Hospital; Nagoya Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Transplantation

Reference41 articles.

1. Japanese experience of ABO-incompatible living kidney transplantation;Tanabe;Transplantation,2007

2. An update on ABO-incompatible kidney transplantation;Zschiedrich;Transpl Int,2015

3. Preconditioning therapy in ABO-incompatible living kidney transplantation: a systematic review and meta-analysis;Lo;Transplantation,2016

4. Trends in ABO-incompatible kidney transplantation;Akikawa;Exp Clin Transplant,2015

5. ABO-incompatible kidney transplantation;Takahashi;Transpl Rev,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3